clinical trial · NCT07139873
A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)
Dizal (Jiangsu) Pharmaceutical Co., Ltd.·phase3·recruiting·n = 250
Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaDZD8586BendamustineIdelalisibRituximab
brief summary
This is a phase 3, open-label, randomized, multi-center study assessing the efficacy and safety of DZD8586 versus investigator's choice in participants with chronic lymphocytic leukemia/small lymphocytic lymphoma who have progressed following prior therapy. Primary objective of this study is to assess the efficacy using progression free survival assessed by independent review committee as primary endpoint. Approximately 250 participants are estimated to be randomized into the study.
started
Sep 8, 2025
primary completion
Jan 1, 2029
completion
Dec 1, 2029
last updated
Mar 27, 2026
official title
A Phase 3, Open-Label, Randomized, Multicenter Study to Evaluate Anti-tumor Efficacy of DZD8586 Versus Investigator's Choice in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol